Vitrakvi is "a treatment for adult and pediatric patients, whose cancers have a specific genetic feature (biomarker)".
Xospata tablets are for the "treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation". This is one the most dangerous forms of blood cancer.
Xospata has been tested in more than 130 patients. The results showed that 21% of patients had a complete reduction or partial blood recovery.
